Paul S. Martin

Hematology
1560 N 115th St
Seattle, WA 98133

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications

Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia.

Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia.

Journal: Blood advances
Published: April 07, 2026

Pretargeted Anti-CD20 Radioimmunotherapy with scFv Fusion Protein Safely Combines with BEAM and ASCT in Patients with High-risk B-cell Lymphomas.

Pretargeted Anti-CD20 Radioimmunotherapy with scFv Fusion Protein Safely Combines with BEAM and ASCT in Patients with High-risk B-cell Lymphomas.

Journal: Molecular cancer therapeutics
Published: July 06, 2024

Anakinra-Associated Systemic Amyloidosis.

Anakinra-Associated Systemic Amyloidosis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: April 13, 2023

Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade.

Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade.

Journal: British journal of haematology
Published: June 23, 2020

A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma.

A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma.

Journal: American journal of hematology
Published: January 24, 2020

Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications.

Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications.

Journal: Experimental hematology
Published: October 14, 2016

Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation.

Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation.

Journal: Haematologica
Published: August 13, 2015
Showing 1-7 of 7

Last Updated: 09/26/2026